Tag
A novel risk score incorporating COPD and graded renal dysfunction improves prediction of one-year mortality post-TAVI, showing excellent internal validity but requiring external validation before clinical use.
A nationwide Medicare study found that women made up a declining share of TAVI patients, had more periprocedural complications, but slightly better long-term survival than men. The findings support sex-specific planning and follow-up in aor
A 10-year Medicare study reveals women face higher immediate risks during TAVI procedures but demonstrate better long-term survival than men, despite declining representation in treatment.
A subgroup analysis of the DEDICATE-DZHK6 trial reveals that TAVI significantly reduces the 1-year risk of death or stroke compared to SAVR in both sexes, with particularly pronounced clinical benefits for women, especially regarding stroke
A substudy of the COMPARE-TAVI 1 trial identifies a unique NF-LEF phenotype in 10.7% of aortic stenosis patients. Despite reduced LVEF, these patients maintain normal flow through eccentric remodeling and achieve clinical improvements post-
The RHEIA trial substudy compares echocardiographic outcomes between TAVI and SAVR in women. While SAVR offers superior LVH regression and lower gradients, TAVI demonstrates significant benefits in preserving right ventricular function and
The landmark BHF PROTECT-TAVI trial reveals that cerebral embolic protection (CEP) does not reduce periprocedural stroke or cognitive impairment following TAVI. This large-scale study challenges the routine use of embolic filters, suggestin
The FAITAVI trial demonstrates that physiology-guided PCI using FFR significantly reduces major adverse cardiac events, particularly mortality, compared to angiography-guided PCI in elderly patients undergoing TAVI with intermediate coronar
The TCW trial randomized 172 patients ≥70 years with severe aortic stenosis and complex coronary disease to FFR-guided PCI plus TAVI versus SAVR plus CABG. At 1 year the percutaneous strategy met non-inferiority and demonstrated superiority
This meta-analysis evaluates 5-year outcomes comparing TAVI and SAVR across risk profiles, revealing early advantages with TAVI that level off long-term, with no significant difference at 5 years.
The COMPARE-TAVI 1 trial demonstrates non-inferiority of Myval transcatheter heart valves compared to SAPIEN 3 THVs at 1-year post-TAVI for a composite clinical endpoint in severe aortic stenosis patients.
The DOUBLE-CHOICE randomized trial demonstrates non-inferiority of isolated local anesthesia versus conscious sedation in transfemoral TAVI, suggesting a safe minimalist anesthesia strategy with potential trade-offs in patient comfort.
The BHF PROTECT-TAVI randomized trial found no cognitive benefit from using cerebral embolic protection devices during transcatheter aortic valve implantation, despite their theoretical role in mitigating embolic brain injury.
The BHF PROTECT-TAVI randomized trial reveals that cerebral embolic protection (CEP) devices do not prevent cognitive decline following transcatheter aortic valve implantation (TAVI), challenging assumptions about their neuroprotective bene
A patient‑level meta‑analysis of randomized trials finds transcatheter aortic valve implantation (TAVI) reduces 1‑year risk of death or stroke versus surgical AVR in low– to intermediate‑risk patients—informing patient selection, heart‑team
The TCW trial demonstrates that FFR-guided PCI plus TAVI is non-inferior and even superior to SAVR plus CABG in elderly patients with severe aortic stenosis and complex coronary artery disease.
Large-scale trials show that routine cerebral embolic protection during TAVI does not significantly reduce early stroke rates, though selective benefits in major stroke and secondary outcomes may exist.
